English (UK)
中文版- 1
- 2
ENRIQUE SANCHEZ
Canadian IVD company with core competencies in the fields of Thrombosis, Haemostasis and oncology, with innovative technologies, we collaborate internationally with technology development companies and health-care stakeholders to develop and manufacture customized reagents and diagnostic solutions.
BIOMEDICA DIAGNOSTICS
Mr.Heather Schwoebel
Alloy is making a humanized transgenic antibody discovery platform, developed within a large pharmaceutical company, broadly available. Our business model includes unlimited access under royalty free terms. Alloy’s strategic plan is to include additional platforms in the protein engineering space that can be synergistically incorporated into our platform, thereby increasing the value offered to licensees.
Alloy Therapeutics
Senior Director of BDDong Sheng
As an investment and management platform established by UK-listed company Cathay International Holdings Limited, Lansen has built up pharmaceutical segment, health segemtn and cosmetic segment. Lansen has been listed in Stock Exchange of Hong Kong Limited (SEHK) on May 7, 2010. Lansen's top products are in rheumatology and dermatology area, and Lansen has established an extensive distribution network, with more than 300 frontline sales staff and more than 1500 distributors. By licensing in promising products at commercial stage and clinical stage, or other cooperation patterns, Lansen plans to expand to more diseases medication market, including rheumaotlogy, dermatology, orthopedics and nephrology.
Lansen Pharmaceutical Holdings Limited
BD Managerh michael shepard
Enosi's lead programs involve novel inhibitors of TNF (tumor necrosis factor), which include severe inflammation associated with viral infections, autoimmune disease, fibrotic diseases, Alzheimer’s, cancer and other diseases. The current TNF inhibitors have important “Black Box” warnings for opportunistic infections, cancer, and cardiovascular events, like stroke. Enosi believes our compounds in development will avoid these limitations of current drugs, be more effective, and will allow expansion into many indications/markets that cannot be approached at the present time by current TNF inhibitors because of their side-effects.
Enosi Life Sciences
CSO and CEODave Sheppard
MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.
MedWorld Advisors
Managing DirectorGeorge Simeon
Curevo is a clinical stage company dedicated to bringing next generation vaccines that offer effectiveness, safety, tolerability, and production advantages to the market, quickly and efficiently.
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development.
Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available.
Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research and GC Pharma.
Curevo's lead product, a Zoster (Shingles) Vaccine, has completed Phase I and shown promising results. We are targeting a unique position in the $20B (by 2030) Varicella Zoster Virus vaccine market.
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development.
Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available.
Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research and GC Pharma.
Curevo's lead product, a Zoster (Shingles) Vaccine, has completed Phase I and shown promising results. We are targeting a unique position in the $20B (by 2030) Varicella Zoster Virus vaccine market.
Curevo Vaccine
CEODr Di Simon
Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).
Wanbang Biopharmaceuticals (Group) Co., Ltd
高级BD经理
Syliva Siu
As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.
Mybiogate Inc.
Haolin Song
GEMSEKI facilitates partnering and licensing activities by using web platform and actively reaching out to potential licensees effectively.
GEMSEKI launched in Oct 2017 as a subsidiary of SNBL a public Japanese company (Tokyo Stock Exchange 2395:JP)
We are looking for assets for in-licensing opportunities of our clients.
Also we have several Japanese and non-Japanese assets in oncology, infection, RA/OA , pain and rheumatoid arthritis available for out-licensing.
GEMSEKI launched in Oct 2017 as a subsidiary of SNBL a public Japanese company (Tokyo Stock Exchange 2395:JP)
We are looking for assets for in-licensing opportunities of our clients.
Also we have several Japanese and non-Japanese assets in oncology, infection, RA/OA , pain and rheumatoid arthritis available for out-licensing.
Responsive Web Design powered by 